Cancer Companion Guide

Executive Summary Over the past several years, repurposed antiparasitic drugs—particularly fenbendazole , mebendazole , and ivermectin —have attracted widespread attention in oncology communities. A publicly accessible compilation hosted by OneDayMD documents more than 500 anecdotal cancer cases reporting tumor regression, stabilization, or remission while using these agents, often in combination with conventional therapy or adjunctive supplements. This report does not treat these anecdotes as proof of efficacy. Instead, it applies pharmacovigilance logic, bias analysis, mechanistic plausibility review, and comparative survival context to assess whether this body of reports constitutes: Noise Wishful thinking Or a legitimate hypothesis-generating signal Conclusion: The dataset does not constitute mainstream clinical evidence. However, the signal density, mechanistic plausibility, and cross-cancer recurrence pattern justify formal prospective evaluation under controlled conditions. 1. ...

Abstract Background: Stage 4 prostate cancer has a 5-year survival rate of 37% with standard of care (SOC, e.g., androgen deprivation therapy [ADT], chemotherapy, Lu-177-PSMA-617). An optimized intervention combining repurposed drugs, supplements, diet/lifestyle, hyperthermia, and SOC components may improve outcomes. Methods : We simulated a double-blind RCT with 1,000 patients (500 per arm) with non-BRCA-mutated stage 4 prostate cancer (70% mHSPC, 30% mCRPC), comparing an integrative multimodal intervention arm (ivermectin 1.0–1.5 mg/kg/day (cycled 3 weeks on/1 off), mebendazole 500–1,500 mg/day (titrated), metformin 1,700 mg/day, vitamin C 1 g/kg IV 3 times/week, vitamin D 5,000 IU/day, curcumin 1,000 mg/day, low-glycemic Mediterranean diet, exercise, MBSR, hyperthermia [modulated electro-hyperthermia at 42°C for 60 minutes, 2–3 times weekly], plus ADT/Lu-177-PSMA-617) to a placebo arm with SOC. Primary endpoint was overall survival (OS); secondary endpoints included progression-fre...

Abstract The Tumor–Node–Metastasis (TNM) classification system, standardized by the American Joint Committee on Cancer (AJCC), remains the global foundation for cancer prognosis and treatment stratification. TNM staging focuses exclusively on tumor burden and anatomical spread. However, mounting evidence suggests that host metabolic factors — particularly insulin resistance and hyperinsulinemia — influence cancer progression, recurrence, and survival independently of tumor stage. This review synthesizes mechanistic, epidemiologic, and interventional evidence linking insulin resistance to oncologic outcomes across multiple malignancies. We examine whether metabolic markers such as fasting insulin, HOMA-IR, and the triglyceride-glucose (TyG) index provide prognostic information beyond TNM classification. While TNM remains indispensable, emerging data support a dual-axis model incorporating tumor burden and metabolic host status. Further prospective trials are required to determine whethe...

The metabolic processes that help your body use food for energy and nourishment are extremely complex. The hormone insulin is a key player. When you eat, sugars from the food enter your bloodstream, which triggers your pancreas to release insulin. That insulin helps the sugar get into your cells to be used for energy. The insulin then ushers any extra sugar to your liver to be stored for later. Insulin also helps your body break down and use lipids, or fats. The amount of insulin in your body goes up and down according to how much sugar is in your bloodstream. But several factors can make your cells resistant to insulin. As a result, your blood sugar and insulin levels will be chronically elevated. Why Obesity and Insulin Resistance Reduce Immunotherapy Effectiveness Short answer: because immunotherapy depends on a metabolically fit immune system — and obesity and insulin resistance reprogram immunity in ways that blunt anti‑tumor response. This article explains how metabolic ...

Cancer staging tells us where the tumor is.  Insulin resistance tells us what kind of body the tumor is growing in. Modern oncology places enormous faith in staging systems. TNM categories, AJCC groupings, and increasingly granular molecular subtypes are used to estimate prognosis, guide treatment, and reassure patients. Yet clinicians and patients alike encounter a persistent paradox: Two patients. Same cancer. Same stage. Same treatment. Radically different outcomes. Staging explains part of the story — but not nearly enough. A growing body of evidence suggests that host metabolic health, particularly insulin resistance, often predicts outcomes more reliably than tumor stage alone. This is not an argument against staging. It is an argument that staging is incomplete. What Cancer Staging Measures — and What It Ignores Cancer staging excels at describing tumor geography : Tumor size Lymph node involvement Distant spread What it largely ignores: Insulin and glucose dynamics Inflamma...